This trade activity should not be overlooked: Intellia Therapeutics Inc. (NTLA)

Intellia Therapeutics Inc. (NASDAQ: NTLA) stock jumped 1.44% on Thursday to $36.01 against a previous-day closing price of $35.50. With 0.76 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.82 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $36.23 whereas the lowest price it dropped to was $35.58. The 52-week range on NTLA shows that it touched its highest point at $69.28 and its lowest point at $32.44 during that stretch. It currently has a 1-year price target of $83.71. Beta for the stock currently stands at 1.84.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NTLA was down-trending over the past week, with a drop of -4.46%, but this was down by -7.21% over a month. Three-month performance dropped to -20.33% while six-month performance fell -11.91%. The stock lost -42.98% in the past year, while it has gained 3.21% so far this year. A look at the trailing 12-month EPS for NTLA yields -5.46 with Next year EPS estimates of -6.20. For the next quarter, that number is -1.49. This implies an EPS growth rate of -63.00% for this year and -11.10% for next year. EPS is expected to grow by 30.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -26.80%.

Float and Shares Shorts:

At present, 88.19 million NTLA shares are outstanding with a float of 83.78 million shares on hand for trading. On Aug 30, 2023, short shares totaled 7.84 million, which was 8.86% higher than short shares on Jul 30, 2023. In addition to Dr. John M. Leonard M.D. as the firm’s Pres, CEO & Director, Mr. Glenn G. Goddard CPA serves as its Exec. VP, CFO & Treasurer.

Institutional Ownership:

Through their ownership of 87.90% of NTLA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 53.38% of NTLA, in contrast to 31.73% held by mutual funds. Shares owned by individuals account for 19.44%. As the largest shareholder in NTLA with 10.81% of the stake, ARK Investment Management LLC holds 9,525,931 shares worth 9,525,931. A second-largest stockholder of NTLA, The Vanguard Group, Inc., holds 8,025,428 shares, controlling over 9.11% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in NTLA, holding 6,867,594 shares or 7.79% stake. With a 7.53% stake in NTLA, the ARK Innovation ETF is the largest stakeholder. A total of 6,639,364 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.97% of NTLA stock, is the second-largest Mutual Fund holder. It holds 2,618,046 shares valued at 110.82 million. Nikko AM Global Umbrella Fund – A holds 2.68% of the stake in NTLA, owning 2,360,401 shares worth 99.92 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, NTLA reported revenue of $14.03M and operating income of -$98.30M. The EBITDA in the recently reported quarter was -$98.47M and diluted EPS was -$1.33.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NTLA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With NTLA analysts setting a high price target of $157.00 and a low target of $38.00, the average target price over the next 12 months is $83.52. Based on these targets, NTLA could surge 335.99% to reach the target high and rise by 5.53% to reach the target low. Reaching the average price target will result in a growth of 131.94% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded NTLA stock several times over the past three months with 1 Buys and 4 Sells. In these transactions, 5,000 shares were bought while 7,492 shares were sold. The number of buy transactions has increased to 22 while that of sell transactions has risen to 15 over the past year. The total number of shares bought during that period was 331,474 while 29,965 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *